Scotti, Andrea, Baggio, Sara, Pagnesi, Matteo, Barbanti, Marco, Adamo, Marianna, Eitan, Amnon, Estévez-Loureiro, Rodrigo, Veulemans, Verena, Toggweiler, Stefan, Mylotte, Darren, De Marco, Federico, Giannini, Francesco, Ferlini, Marco, Naber, Christoph K., Buono, Andrea, Schofer, Joachim, Rottbauer, Wolfgang, Van Mieghem, Nicolas M., Khogali, Saib, Taramasso, Maurizio, Pilgrim, Thomas, Sinning, Jan Malte, Zweiker, David, Montorfano, Matteo, Van Der Heyden, Jan A.S., Brugaletta, Salvatore, Ielasi, Alfonso, Hamm, Christian W., Vanhaverbeke, Maarten, Costa, Giuliano, Massussi, Mauro, Alarcón, Robert, Zeus, Tobias, Lunardi, Mattia, Testa, Luca, Di Ienno, Luca, Lanzillo, Giuseppe, Wolf, Alexander, Maffeo, Diego, Ziviello, Francesca, Saccocci, Matteo, Windecker, Stephan, Sedaghat, Alexander, Schmidt, Albrecht, Brouwer, Jorn, Regueiro, Ander, Reimers, Bernhard, Kim, Won Keun, Sondergaard, Lars, Colombo, Antonio, Mangieri, Antonio, Latib, Azeem, Scotti, Andrea, Baggio, Sara, Pagnesi, Matteo, Barbanti, Marco, Adamo, Marianna, Eitan, Amnon, Estévez-Loureiro, Rodrigo, Veulemans, Verena, Toggweiler, Stefan, Mylotte, Darren, De Marco, Federico, Giannini, Francesco, Ferlini, Marco, Naber, Christoph K., Buono, Andrea, Schofer, Joachim, Rottbauer, Wolfgang, Van Mieghem, Nicolas M., Khogali, Saib, Taramasso, Maurizio, Pilgrim, Thomas, Sinning, Jan Malte, Zweiker, David, Montorfano, Matteo, Van Der Heyden, Jan A.S., Brugaletta, Salvatore, Ielasi, Alfonso, Hamm, Christian W., Vanhaverbeke, Maarten, Costa, Giuliano, Massussi, Mauro, Alarcón, Robert, Zeus, Tobias, Lunardi, Mattia, Testa, Luca, Di Ienno, Luca, Lanzillo, Giuseppe, Wolf, Alexander, Maffeo, Diego, Ziviello, Francesca, Saccocci, Matteo, Windecker, Stephan, Sedaghat, Alexander, Schmidt, Albrecht, Brouwer, Jorn, Regueiro, Ander, Reimers, Bernhard, Kim, Won Keun, Sondergaard, Lars, Colombo, Antonio, Mangieri, Antonio, and Latib, Azeem
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P<0.001) and more moderate or heavy valve calcification (Q1–4, 80%, 80%, 82%, 88%; P=0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1–4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P=0.023) and early safety (Q1–4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P<0.001), with fewer permanent pacemaker implantations (Q1–4: 15.3%, 20.0%, 12.1%, 11.6%; Cochran-Armitage P=0.023) and residual mild or greater paravalvular leaks (Q1–4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P<0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-e, Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim of this study was to investigate temporal trends and assess contemporary outcomes after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This study included patients enrolled in the multicenter NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) and NEOPRO-2 (A Multicenter Comparison of ACURATE NEO2 Versus Evolut PRO/PRO+ Transcatheter Heart Valves 2) registries who underwent transfemoral TAVR with Evolut PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified in quartiles (Q) and used to investigate temporal trends in TAVR outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, and 1-year outcomes were evaluated. Results: In total, 1616 patients from 28 centers were included. Over time, patients had lower Society of Thoracic Surgeon-Predicted Risk of Mortality score (Q1-4, 4.1% [2.8-6.3%], 3.7% [2.6-5.3%], 3.3% [2.4-4.9%], 2.9% [2.2-4.3%]; P<0.001) and more moderate or heavy valve calcification (Q1-4, 80%, 80%, 82%, 88%; P=0.038). Overall Valve Academic Research Consortium-3 technical success was 94.1%, with 30-day and 1-year all-cause mortality of 2.4% and 10%, respectively. Throughout the study period, procedures were associated with higher rates of 30-day device success (Q1-4, 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage P=0.023) and early safety (Q1-4, 66.8%, 67.5%, 74.0%, 77.6%; Cochran-Armitage P<0.001), with fewer permanent pacemaker implantations (Q1-4: 15.3%, 20.0%, 12.1%, 11.6%; Cochran-Armitage P=0.023) and residual mild or greater paravalvular leaks (Q1-4, 50.4%, 42.1%, 36.5%, 35.8%; Cochran-Armitage P<0.001). Conclusions: TAVR with Evolut PRO/PRO+ self-expanding valve is safe and effective. De